The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study

BACKGROUND: PD-1/L1 inhibitor-based immunotherapy is currently under investigation in biliary tract cancer (BTC). Apatinib combined with camrelizumab has achieved promising results in various tumor types. The aim of this study was to assess the safety and efficacy of apatinib plus camrelizumab for a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Dongxu, Yang, Xu, Long, Junyu, Lin, Jianzhen, Mao, Jinzhu, Xie, Fucun, Wang, Yunchao, Wang, Yanyu, Xun, Ziyu, Bai, Yi, Yang, Xiaobo, Guan, Mei, Pan, Jie, Seery, Samuel, Sang, Xinting, Zhao, Haitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071846/
https://www.ncbi.nlm.nih.gov/pubmed/33912461
http://dx.doi.org/10.3389/fonc.2021.646979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071846/
https://www.ncbi.nlm.nih.gov/pubmed/33912461
http://dx.doi.org/10.3389/fonc.2021.646979

Ejemplares similares